Evidence map›Paper›PMID 32303884›Full record

Trial reportJournal of anesthesia2020

Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial.

Matsuyuki Doi, Naoyuki Hirata, Toshiyasu Suzuki, Hiroshi Morisaki, Hiroshi Morimatsu, Atsuhiro Sakamoto

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of anesthesia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06009991 (The Investigation of the Dose Range of Remimazolam Besylate in Different Age Groups of Adults and Its Effects on Hemodynamics), which is not on this map. Cited by 160 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 2 pooled it
32.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06009991 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Investigation of the Dose Range of Remimazolam Besylate in Different Age Groups of Adults and Its Effects on Hemodynamics

TypeinterventionalSponsorTongji HospitalRan2023 to 2025Enrolled1,876ConditionsRemimazolam, AnesthesiaArmsRemimazolam besylate, Propofol
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 2 syntheses or guidelines pooled it, 231 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Matsuyuki DoiDepartment of Anesthesiology and Intensive Care, Hamamatsu University Hospital, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan. matsuyuki_doi@nifty.com.
Naoyuki HirataDepartment of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Toshiyasu SuzukiDepartment of Anesthesiology, Tokai University of Medicine, Isehara, Japan.
Hiroshi MorisakiDepartment of Anesthesiology, Keio University School of Medicine, Tokyo, Japan.
Hiroshi MorimatsuDepartment of Anesthesiology and Resuscitology, Okayama University Hospital, Okayama, Japan.
Atsuhiro SakamotoDepartment of Anesthesiology, Nippon Medical School, Tokyo, Japan.
Hamamatsu University · JPKeio University · JPNippon Medical School · JPOkayama University Hospital · JPSapporo Medical University · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRemimazolam, an ultra-short-acting benzodiazepine sedative is equally effective as propofol in induction and maintenance of general anesthesia with improved hemodynamic stability in American Society of Anesthesiologists (ASA) Class I and II patients. This trial investigated remimazolam's efficacy and safety in vulnerable patients (ASA Class III) undergoing elective general surgery.

methodsA multicenter, randomized, double-blind, parallel-group trial in 67 adult surgical patients undergoing general anesthesia with two remimazolam induction doses (6 mg kg

resultsThe functional anesthetic capability of the investigated drug was 100% in both arms. The mean time to loss of consciousness (LoC) was significantly shorter in group B (81.7 s) compared to group A (97.2 s), p = 0.0139. The mean bispectral index (BIS) value during maintenance of anesthesia ranged from 46.0 to 68.0 and from 44.7 to 67.5 in group A and B, respectively. There was no statistically significant difference between the remimazolam arms concerning the incidence of blood pressure (BP) decrease (67.7% in group B vs. 54.8% in group A), recovery profile or the incidence or severity of adverse events (AEs) or adverse drug reactions (ADRs).

conclusionBoth induction regimens (6 and 12 mg kg

Indexed as

MidazolamPropofolAdultAnesthesia, GeneralBenzodiazepinesDouble-Blind MethodHumansHypnotics and SedativesJapanMaintenanceBenzodiazepinesHypnotics and SedativesMidazolamPropofolremimazolamASA 3CNS7056General anesthesiaONO-2745Remimazolam

Identifiers

PMID32303884
OpenAlexW3016871582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.